Oncology Peer Review On-The-Go: ScaleReady’s Work to Make Cell and Gene Therapy Practical and Viable

Data from a prospective pilot study indicate that circulating tumor DNA may be a valuable prognostic biomarker in early-stage follicular lymphoma.

Suneel D. Kamath, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on how financial conflicts of interest correlate with success of early-career academic oncologist.

Findings from the phase 3 DeFi trial support the new drug application for nirogacestat as a treatment for adults with desmoid tumors.

Nora Janjan, MD, MPSA, MBA, spoke with CancerNetwork® about the latest perspective from the journal ONCOLOGY® on how roles and responsibilities of academic clinicians in reporting of conflicts of interest influence oncology research.

Rahul Banerjee, MD, FACP, recounts the recent Tandem meeting by highlighting an interesting study involving cell phones and cell therapies.

Adverse effects including light sensitivity and blurred vision lead to a clinical hold in enrollment for the phase 1/2 VERA trial evaluating BLU-222 in advanced solid tumors.